Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Adenosine pathway as a therapeutic target in diffuse large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMiranda McGaskeyECEthel Cesarman

Discussion

Loading...

Member takes

Overview

Observational analysis shows potential for adenosine pathway inhibitors to improve tumor immunity in DLBCL.

Key Points

  • Inhibition of adenosine signaling enhances tumor immunity, with significant effects noted in B6 mice.
  • High levels of extracellular ATP contribute to immunosuppression in solid tumors, affecting B cell response.
  • Immunohistochemistry revealed CD39 and CD73 expression in DLBCL, with implications for targeted therapy.
  • Enhanced survival observed in tumor-bearing B6 mice treated with A2AR antagonist, supporting therapeutic strategies.

Cite This Study

McGaskey et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db3fhttps://doi.org/10.1182/blood-2025-5345
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Arginine deprivation activates immunogenic cell death and enhances anti-tumor immunity in diffuse large B-cell lymphoma2025
  2. 2A2AR-mediated inhibition of B cell maturation: a novel mechanism of immune suppression in cancer2025
  3. 3Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in Diffuse Large B Cell Lymphoma (DLBCL)2025
  4. 4CD40L and IL-4 suppress NK cell-mediated ADCC through the HLA-E:NKG2A axis2025 · 3 citations
  5. 5Polatuzumab vedotin and <scp>CD79B</scp>: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma2025